Insider buying roundup: Atlassian CEO Mike Cannon-Brookes, Bloomin' Brands and Flagstar CEOs buy

Atlassian CEO Mike Cannon-Brookes bought 13,400 shares for $2.01M. Juniper Investment bought 689,803 Orthofix shares for $5.1M, now owning 13.4%. Bloomin' Brands and Flagstar CEOs each bought ~$500K in stock. Other insider buys include Claritev, Pampa Energia, Hudson Pacific, and ADTRAN.

Original reporting
Published Nov 13, 2026, 4:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 14, 2026, 12:50 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$TEAM
Bullish
high confidence
Mentioned
$TEAM · $BLMN · $OFIX
Relevance
4/10
AlphAI data visualization · based on mlq.ai
Decision brief

The 30-second read

$TEAMBullishLow
01

Why it matters

While each purchase provides a modest confidence cue, the overall market impact is limited due to the modest size and pre‑planned nature of the trades.

02

Market read

Insider buying signals modest positive sentiment for the four companies but does not constitute a strong trading catalyst.

03

What to watch

The purchases were pre‑planned under 10b5‑1 plans, reducing the informational edge of the trades.

Relevance 4/10Novelty 4/10Timing: after‑hours filing on Nov 12

Background

The article aggregates recent Form 4 filings and a 13D filing, summarizing insider purchases across several U.S. listed companies.

Company-level read

Ticker impact

$TEAMBullishHigh confidence
Context

CEO Mike Cannon-Brookes bought 13,400 shares (~$2.01M) via a 10b5‑1 plan, the first insider purchase disclosed since February.

Expected impact

likely slight buying pressure as market digests the purchase

Evidence & confidence

Form 4 is a primary source; the purchase size is material for a single insider and the stock recently fell on guidance, so the buy may temper the decline.

$BLMNBullishMedium confidence
Context

Bloomin' Brands CEO Mike Spanos purchased 50,000 shares (~$502K) on Nov 11.

Expected impact

minor upside potential

Evidence & confidence

Small insider buy relative to market cap; limited impact but could support short‑term sentiment.

$OFIXBullishMedium confidence
Context

Juniper Investment bought 689,803 Orthofix shares (~$5.1M), raising its stake to 13.4%.

Expected impact

potential modest rally

Evidence & confidence

Stake increase above 10% is notable; however, the company is a small‑cap medical‑device firm, so market reaction likely limited.

Market effects

Insider activity highlights confidence in tech, restaurant, banking, and med‑device sectors but unlikely to shift sector trends.

U.S. equities only; no broader regional effect.

Limited to the individual stocks mentioned.

Counterpoint

Insider purchases may be routine portfolio rebalancing rather than a genuine bullish signal.

Key entities

  • Mike Cannon‑Brookes

    CEO of Atlassian

  • Mike Spanos

    CEO of Bloomin' Brands

  • Joseph Otting

    CEO of Flagstar Bank

  • Juniper Investment

    Investor increasing stake in Orthofix

Related articles

$OFIXHighAI 8/10

Orthofix Earnings Call Shows Growth Amid Spine Challenges

Orthofix Medical reported Q3 revenue of $207.9M, up 2.3% YoY. Limb Reconstruction and Therapeutic Solutions grew 9% and 4%, respectively, while U.S. Spine declined 5%. Adjusted EBITDA improved to $26M. Management lowered 2026 guidance, citing Spine market softness and supply issues, but expects 2027 core revenue growth excluding MDR impact.

Med

Orthofix Medical Inc. Q3 2026 Earnings Call Summary

Orthofix Medical Inc. reported Q3 2026 earnings below expectations due to U.S. Spine market softness and supplier delays. The company is consolidating distributors, with core partners generating 80% of U.S. spinal implant revenue. Updated full-year 2026 revenue guidance is $825M-$830M. Management expects a $22M net sales headwind in 2027 due to European MDR requirements. The VIRATA spinal implant system is set for full market launch in late Q4 2026.

$OFIXMedAI 8/10

Orthofix Medical (OFIX) Q3 2026 Earnings Call Transcript

Orthofix Medical (OFIX) reported Q3 2026 net sales of $207.9M, up 2.3% YoY. Spine sales fell 1%, while Limb Reconstruction and Therapeutic Solutions grew 9% and 4%, respectively. The company is focusing on strategic partnerships, simplifying its product portfolio, and aligning costs. It expects near-term sales pressure due to these transitions and updated guidance accordingly. Cash reserves stood at $86.9M.

$OFIXMed

Orthofix 3Q 2026: Revenue $207.86M, EPS ($0.15) — 10-Q Summary

Orthofix reported 3Q 2026 revenue of $207.86M, up 1.1% YoY, with a net loss of $6.07M, improved from $22.8M last year. Therapeutic Solutions and Global Limb Reconstruction sales grew, while Spinal Implants and other segments declined. Gross margin fell to 70.5% due to product mix changes. SG&A expenses decreased by $22.8M, driven by lower legal costs and commissions.